- All regions
- Asia
Hong Kong
India
Japan
Korea, Republic of
Singapore
Taiwan- Australasia
Australia
New Zealand- Europe
Austria
Belgium
Bosnia Herzegovina
Bulgaria
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Macedonia
Netherlands
Norway
Poland
Portugal
Romania
Serbia Montenegro
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
United Kingdom- North America
Canada
United States
Top stocks in United States
| Name | Market Cap | Price to Earnings TTM | Dividend Yield % TTM |
|---|---|---|---|
 TLSITriSalus Life Sciences | $272.07m | n/a | n/a |
| IKTInhibikase Therapeutics | $271.99m | n/a | n/a |
| HVIIUHennessy Capital Investment VII | $271.29m | 70.91 | n/a |
| HVIIHennessy Capital Investment VII | $271.29m | 68.45 | n/a |
| ESCAEscalade | $271.27m | 17.62 | 3.07% |
| BIOSUBioPlus Acquisition | $271.27m | 52.4 | n/a |
| BIOSBioPlus Acquisition | $271.14m | 52.37 | n/a |
| AACOAbony Acquisition I | $270.56m | n/a | n/a |
| HCKTHackett | $270.53m | 17.06 | 4.47% |
| SVIVUSpring Valley Acquisition. IV | $270.40m | n/a | n/a |
| CAQUUCambridge Acquisition | $270.27m | n/a | n/a |
| RDCMRadcom | $270.16m | 19.7 | n/a |
| MUZEMuzero Acquisition | $269.92m | n/a | n/a |
| CHRSCoherus Oncology | $269.88m | n/a | n/a |
| CEPOCantor Equity Partners I | $269.56m | n/a | n/a |
| SVIVSpring Valley Acquisition. IV | $269.33m | n/a | n/a |
| FLICFirst of Long Island | $269.21m | 15.52 | 7.08% |
| ARTVArtiva Biotherapeutics | $269.16m | n/a | n/a |
| DNMXUDynamix III | $267.80m | 345.98 | n/a |
| DNMXDynamix III | $267.80m | n/a | n/a |